CXCR2 and chronic obstructive pulmonary disease: Danirixin (GSK1325756) is a reversible CXCR2 antagonist originally developed as an anti-inflammatory agent for disorders associated with neutrophil accumulation, such as chronic obstructive pulmonary disease.79 As neutrophil infiltration is an important component of RSV pathogenesis, a clinical trial was initiated to determine the capacity of danirixin to inhibit neutrophil activation in RSV-infected infants.